Tag: preclinical
-
Myelin Foundation to Assess Multiple Sclerosis Treatment
Myelin Repair Foundation in Saratoga, California is collaborating with drug development company Bionure Inc. in Barcelona, Spain to evaluate Bionure’s compound BN201 as a therapy candidate for multiple sclerosis. Financial aspects of the agreement were not disclosed. Multiple sclerosis is a condition where the immune system attacks the central nervous system and damages the fatty,…
-
Peptide Developed to Combat Antibiotic-Resistant Bacteria
Researchers at University of Copenhagen in Denmark and University of British Columbia in Canada developed and tested in the lab a substance they say quickly and effectively kills multiple types of bacteria, including those resistant to current antibiotics. The team led by Copenhagen’s Henrik Franzyk and UBC’s Robert Hancock published their findings last week in the…
-
Heat, Iron-Oxide Nanoparticles Improve Cancer Drug Delivery
Pharmaceutical and engineering researchers at Oregon State University in Corvallis developed a technique with heated iron-oxide nanoparticles that in lab tests was shown to kill ovarian cancer cells with chemotherapy drugs. The team led by Oregon State pharmacy professor Oleh Taratula published its findings this month in an advance online paper in the International Journal of…
-
Genetic-Based Antibiotic Found Effective in Lab Tests
Researchers at Oregon State University, University of Texas Southwestern Medical Center, and the biotechnology company Sarepta Therapeutics tested in lab mice an antibiotic developed from synthetic genetic material that kills bacteria resistant to traditional antibiotics. Their findings appear online today in the Journal of Infectious Diseases (paid subscription required). The team from the labs of…
-
Pfizer Licenses University Institute’s Obesity Research
The global pharmaceutical company Pfizer is funding research at Université de Montréal in Quebec, Canada to identify cellular pathways in genetic defects leading to therapies for early-onset morbid obesity. Financial aspects of the collaboration, which gives Pfizer a license to commercially develop results of the research, were not disclosed. Pfizer is funding and licensing research…
-
Cleveland Clinic Spin-Off Developing Breast Cancer Vaccine
Shield Biotech, a spin-off company from the Cleveland Clinic in Ohio, is creating a vaccine to prevent breast cancer based on research conducted at the clinic’s research institute. Vincent Tuohy, a Cleveland Clinic immunologist, founded the company with the clinic’s commercialization division, and serves as its chief scientist. Tuohy’s research seeks to find a method for protecting…
-
Bayer, Compugen to Partner on Cancer Immunotherapies
The pharmaceutical company Bayer HealthCare in Berlin and drug discovery company Compugen Ltd in Tel Aviv, Israel agreed on a development and licensing deal for two potential cancer therapies discovered by Compugen that harness the body’s immune system. The deal has a potential value to Compugen of at least $540 million. Compugen uses computational biology,…
-
Cell Therapy Technique Tested to Regenerate Back Discs
Biomedical engineers at Duke University in Durham, North Carolina developed a new biomaterial to deliver cells that repair the cushions between spinal discs and relieve the pain when that material degenerates. The team led by biomedical engineering professor Lori Setton — with colleagues from Duke, Singapore, and Taiwan — published their proof-of-concept findings last week…
-
AstraZeneca, Roche to Share Preclinical Research Data
The global pharmaceutical companies AstraZeneca and Roche agreed to share early-stage drug research data to speed product development and identify candidates with a greater chance of success. Financial aspects of the collaboration were not disclosed. The two companies will furnish their research data on investigational compounds to a third party, MedChemica, a computational chemistry service…
-
Pharmas, Academics Partner on New Treatments from Old Drugs
Researchers from pharmaceutical companies and academic labs are partnering on finding therapies for eight types of diseases from drugs tested to treat other disorders. The $12.7 million pilot program, led by National Center for Advancing Translational Sciences (NCATS), part of National Institutes of Health, funds nine separate projects combining industry and university scientists for up…